ARQT News and Press, Arcutis Biotherapeutics Inc. From 02/26/24

2024-02-26 16:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-23 15:00:00 ET More on the markets SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat SPY: The U.S. Is Positioned To Expand Its Global Dominance S&P 500: Correction In Progress, Deeper Selloff Expec...

2024-02-16 09:45:10 ET Coinbase Global Inc (COIN) COIN is trading UP for the last 5 days, and it at trading at $186.09 with volume of 16,349,983 and a one day change of $20.42 (12.33%). Coinbase Global Inc has a 52-week low of 32.58 and a 52-week high of $121.46. The business's 50-d...

Quarterly investor conference call and webcast scheduled for Tuesday, February 27 at 8:30 a.m. ET WESTLAKE VILLAGE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful i...

2024-02-16 07:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is one of today's top gainers. The company's shares have moved 14.91% on the day to $6.55. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product...

2024-02-01 08:29:22 ET More on pre-market losers & stocks. Bullfrog AI stock rallies 32% on early brain research results Infobird announces new business deal in software development of information technology system Financial information for Bullfrog AI Holdings, ...

2024-01-31 17:40:53 ET More on Arcutis Biotherapeutics Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture Mizuho upgrades Arcutis to buy, cites Zoryve sales Read the full article on Seeking Alpha For further details see: Arcutis Biotherapeuti...

WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggen...

2024-01-31 03:09:25 ET Summary Arcutis is a late-stage biopharmaceutical company focused on developing treatments for immune-mediated dermatological diseases. The company has received FDA approval for its topical cream, Zoryve, for the treatment of plaque psoriasis and seborrheic ...